Ethical, Scientific Issues Related To 'Post-Market' Clinical Trials

Report: ethical, scientific issues related to 'post-market' clinical trials


Amid growing concerns about clinical trials for drugs that have been approved by the F.D.A. but are later linked to serious health risks, an independent committee at the Institute of Medicine led by two professors from Johns Hopkins University has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.